ARB 1740

Drug Profile

ARB 1740

Alternative Names: ARB-1740

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arbutus Biopharma
  • Class Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 24 Oct 2017 Updated pharmacodynamics data from a preclinical trial in Hepatitis B presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 03 Oct 2017 Pharmacodynamics data from a preclinical trial in Hepatitis B released by Arbutus Biopharma
  • 03 Aug 2017 Arbutus Biopharma completes a phase II trial in Hepatitis B in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top